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Abstract
The current standard of care for gastric cancer imaging includes heterogeneity in image acquisition techniques and qualitative image
interpretation. In addition to qualitative assessment, several imaging techniques, including diffusion-weighted magnetic resonance
imaging (DW-MRI), contrast-enhanced multidetector computed tomography (CE-MDCT), dynamic-contrast enhanced MRI and
18F-fluorodeoxyglucose positron emission tomography, can allow quantitative analysis. However, so far there is no consensus
regarding the application of functional imaging in the management of gastric cancer. The aim of this article is to specifically review
two promising biomarkers for gastric cancer with reasonable spatial resolution: the apparent diffusion coefficient (ADC) from DW-
MRI and textural features from CE-MDCT. We searched MEDLINE/ PubMed for manuscripts published from inception to 6
February 2018. Initially, we searched for (gastric cancer OR gastric tumour) AND diffusion weighted magnetic resonance imaging.
Then, we searched for (gastric cancer OR gastric tumour) AND texture analysis AND computed tomography.We collated the results
from the studies related to this query. There is evidence that: (1) the ADC is a promising biomarker for the evaluation of the
aggressiveness (T and N stage), treatment response and prognosis of gastric cancer; (2) textural features are related to the degree of
differentiation, Lauren classification, treatment response and prognosis of gastric cancer.We conclude that these imaging biomarkers
hold promise as effective additional tools in the diagnostic pathway of gastric cancer and may facilitate the multidisciplinary work
between the radiologist and clinician, and across different institutions, to provide a greater biological understanding of gastric cancer.
Key Points
• Quantitative imaging is the extraction of quantifiable features from medical images for the assessment of normal or patholog-
ical conditions and represents a promising area for gastric cancer.
• Quantitative analysis from CE-MDCT and DW-MRI allows the extrapolation of multiple imaging biomarkers.
• ADC from DW-MRI and CE- MDCT-based texture features are non-invasive, quantitative imaging biomarkers that hold
promise in the evaluation of the aggressiveness, treatment response and prognosis of gastric cancer.
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Introduction
Gastric cancer is one of the most common malignancies
worldwide [1].
The recommended management of this disease is a
standardised multidisciplinary approach, which involves sur-
gery, neoadjuvant and adjuvant chemotherapy. Surgical pa-
thology is the reference standard for staging gastric cancer,
and the Tumour, Node, Metastasis (TNM) classification is
the most important tool for an adequate therapeutic plan and
for predicting treatment response and prognosis [2]. Imaging
plays a crucial role in the detection, staging, treatment plan-
ning and follow-up of this disease [3, 4].
A biomarker indicates a biological process (normal or path-
ological) both at baseline and after therapeutic interventions
[5]. Oncological imaging represents an ideal setting for the
collection of new biomarkers from different techniques, as
oncological patients usually undergo multiple imaging studies
[6]. The European Society of Radiology published a white
paper on imaging biomarkers that underlined their importance
as non-invasive, quantitative tools with different applications
in oncology [7]. The Radiological Society of North America
has also promoted the use of imaging biomarkers in clinical
trials [8].
Quantitative imaging is the extraction of quantifiable fea-
tures from medical images to assess normal or pathological
conditions [9, 10].
There is a wide range of imaging biomarkers from different
techniques. It is possible to extrapolate multiple imaging bio-
markers through quantitative analysis of data derived from
different techniques, such as contrast-enhanced multidetector
computed tomography (CE-MDCT), diffusion-weighted
magnetic resonance imaging (DW-MRI), dynamic contrast-
enhanced (DCE)-MRI and 18F-fluorodeoxyglucose positron
emission tomography (18F-FDG-PET) [11–19].
While reviews and meta-analyses of other imaging modal-
ities (e.g. 18 FDG-PET) have been already carried out
[20–25], this is the first time that a critical review has been
specifically designed to summarise the state of the art of im-
aging biomarkers such as ADC from DW-MRI and texture
features from CE-MDCT in gastric cancer.
Currently, there are only a few defined diagnostic and prog-
nostic biomarkers for gastric tumours but none are related to
imaging techniques [26–28].
In an attempt to overcome such limitations, in this review
we specifically provide the state of the art on the use of two
imaging biomarkers: the apparent diffusion coefficient (ADC)
from DW-MRI and texture features from CE-MDCT.
Evidence acquisition
We searched MEDLINE/ PubMed for manuscripts published
from inception to 6 February 2018. Initially we searched for
(gastric cancer OR gastric tumor) AND diffusion weighted
magnetic resonance imaging. Then, our search included (gas-
tric cancer OR gastric tumour) AND texture analysis AND
computed tomography. Figure 1 shows the literature search
and study selection.
5 arcles 
on texture analysis 
from CE-MDCT and gastric cancer 
1 record not relevant 
to research queson
6 records idenﬁed
11 arcles 
on imaging biomarkers 
from DW-MRI and gastric cancer 
63 records not relevant 
to research queson
74 records idenﬁed
5 arcles 
(TNM staging)
4 arcles 
(treatment response) 
2 arcles 
(prognosis) 
a b
Fig. 1 Flow diagrams showing the outcome of the initial searches resulting in the full studies included in the review for diffusion-weighted magnetic
resonance imaging (DW-MRI) (a) and contrast-enhanced multidetector computed tomography (CE-MDCT) (b)
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DW-MRI and imaging biomarkers
Eleven studies on DW-MRI were relevant to our query, and
they were assessed in full.
Basic concepts of DW-MRI
DW-MRI measures the mobility of water molecules within
tissues. Water diffusion is restricted in highly cellular tissues
such as tumours, but some conditions (fibrosis/inflammation)
can also show restricted diffusion [29].
Tissues with higher cellularity result in higher signal intensi-
ty on DWI. The b value is a parameter that identifies the mea-
surement's sensitivity to water diffusion. The optimal b value
should attenuate the healthy background tissue more than the
lesion, with a reasonable signal-to-noise ratio at the same time.
The greater the b value is, the stronger the DWI signal and the
detection of pathological areas [29]. It is possible to generate a
dedicated map that enables the calculation of the ADC. An area
of higher signal intensity on DWI appears as a low-signal in-
tensity on the ADC map. The region of interest (ROI) from
which the ADC is calculated can be drawn as a small area or
as a larger area encompassing thewhole tumour on a single slice
(Fig. 2). The ADC can also be obtained drawing the ROIs on all
the slices where the tumour is visible (planimetry). This param-
eter is therefore a quantitative measurement of the mobility of
water molecules within tissues and tumours, given their higher
cellularity, have lower ADC values than normal areas [30].
DW-MRI to assess the aggressiveness of gastric cancer
MRI of abdominal organs is often influenced by macroscopic
motion. Imaging acquisition should be performed with breath-
hold or respiratory triggering sequences, after the administration
of intravenous/intramuscular anti-peristaltic agents and oral wa-
ter to distend the gastric lumen [30, 31].
Growing evidence supports the use of DW-MRI in the
assessment of the aggressiveness of gastric cancer [32–43].
Table 1 summarises the recent studies that have addressed this
topic by analysing the role of ADC.
Cheng et al [38] calculated ADC of pathological lymph
nodes (dimensional criteria ≥ 5 mm in short-axis diameter)
on a pixel-by-pixel base. After extended lymphadenectomy,
metastatic lymph nodes showed lower median ADC than be-
nign lymph nodes (1.28 vs. 1.55 × 10-3 mm2/s, p < 0.001). A
cut-off of 1.39 × 10-3 mm2/s could discriminate between path-
ological and benign lymph nodes with a sensitivity of 85.7%
and specificity of 79.4%. Quantitative results were also com-
pared with morphological factors including size, border irreg-
ularity and enhancement patterns. The authors concluded that
ADC holds promise to identify metastatic lymph nodes in gas-
tric cancer. Their results are relevant, but lymph nodes < 5 mm
were not evaluated because of the limited resolution of DWI.
Liu et al [35] conducted a retrospective studywhere themean
andminimumADCs of gastric cancer were calculated and com-
pared with surgical specimens. Both parameters showed a sig-
nificant difference in detecting the different degrees of local
invasion and nodal involvement. In particular, the correlation
Fig. 2 The arrows indicate a tumour of the lesser curvature on T2-
weighted imaging (a) and on diffusion-weighted magnetic resonance
imaging (DW-MRI) using different b values (b–e). The apparent
diffusion coefficient (ADC) is calculated on the ADC map (f) from a
small (red) or large (yellow) region of interest (red) on a single slice
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(r) with postoperative T staging was -0.464 (mean ADC) and
-0.476 (minimum ADC) (p < 0.001), while the correlation (r)
with postoperative N staging was -0.402 (mean ADC) and
-0.397 (minimum ADC) (p = 0.001 and 0.002, respectively).
The same group conducted a whole-lesion ADC histogram
analysis in 80 patients comparing the results with radical spec-
imens [43]. Significant differences for all ADC parameters
with respect to T and N stages were found. In particular, the
ADC10% provided the largest area under the curve (0.794) to
identify nodal involvement.
Liu et al [34] investigated the role of whole-volume ADC-
based entropy (a parameter describing tumour heterogeneity)
in the preoperative assessment of gastric cancer. Entropy-
related parameters from the ADCmap significantly correlated
with postoperative T, N and overall stage as well as vascular
and perineural invasion.
Conversely, Hasbahceci et al [42] showed that it is not
feasible to evaluate nodal involvement in gastric cancer by
means of ADC. The cohort comprised 23 patients and ADC
did not differentiate between benign and metastatic lymph
nodes. However, the accuracy of DW-MRI in identifying met-
astatic lymph nodes in this study was 52.17%, 65.21% and
69.56% for group Ia, Ib and II, respectively. The overall accu-
racy of N-staging based on DW-MRI was 13%. The lack of
motion correction manoeuvres and the small number of pa-
tients represent important limitations of this study.
Zhong and colleagues [41] showed that pathological lymph
nodes have a lower ADC than benign lymph nodes (1.15 vs.
1.48 × 10-3 mm2/s, respectively; p <0.001). The same group
compared the results from DWI with morphological MRI (T2-
weighted imaging) and CE-MDCT; the combination of the
three techniques yielded the highest area under the curve
(0.893) for nodal involvement. The results are interesting, but
a rigorous radiological-pathological correlation could not be
assessed because of the large number and complex anatomic
location of lymph nodes in gastric cancer. Another study [37]
conducted on 89 patients reported that ADC is different accord-
ing to local invasion, nodal involvement and the 7th TNM
edition stage groups (p < 0.001). Therefore, there is evidence
that ADC is a promising, non-invasive imaging biomarker for
the evaluation of the aggressiveness of gastric cancer.
DW-MRI in treatment response of gastric cancer
In recent years, there has been considerable interest in the
application of DW-MRI to assess treatment response in gastric
cancer [44–48]. Table 2 reports the main studies that have
addressed this topic by means of ADC. Two studies from the
same centre [46, 47] showed that ADC could be considered a
reliable indicator of treatment response. De Cobelli et al [46]
analysed ADC before and after treatment and compared the
results with tumour volume, considering tumour regression
grade (TRG) as the reference standard [49]. RespondersTa
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showed a significant increase in ADC compared with non-
responders (85.45% increase vs. 8.21% decrease, respectively:
p < 0.001). However, this study also included patients with
oesophageal cancer. Similar results [47] were found comparing
ADC and standardised uptake volume (SUV) values in 17 pa-
tients undergoing DW-MRI and PET, before and after therapy.
Changes in ADC were correlated with TRG (r = -0.78; p <
0.001), while SUV did not yield significant results. The results
from this study are promising even though the number of patients
is small (n = 17).
Lee and colleagues [44] investigated the usefulness of
PET/MRI in predicting treatment response for advanced,
unresectable gastric cancer in 11 patients. In addition to
ADC, SUV and perfusion parameters were calculated prior
to chemotherapy. Response to treatment was evaluated on
the basis of the response evaluation criteria in solid tumours
(RECIST) 1.1 criteria [50]. Differently from perfusion param-
eters, ADC and SUV were not significantly different between
responders and non-responders. However, the lack of both
post-treatment imaging and comparison with surgical speci-
mens represents an important limitation of this study.
Zhong and colleagues [45] conducted a study on 106 pa-
tients with biopsy-proven gastric cancer undergoing DW-MRI
before and after chemotherapy at different time points. Mean
ADC was calculated for benign and metastatic lymph nodes,
and response to treatment was evaluated on the basis of the
RECIST 1.1 criteria [50]. ADC significantly increased after
treatment in all groups (complete response, partial response
and stable disease group), predicting nodal response to neo-
adjuvant therapy. These studies support the potential role of
DW-MRI in tailoring the therapeutic plan for gastric cancer
(Fig. 3).
DW-MRI in the prognosis of gastric cancer
At present, two studies [37, 51] have shown that ADC can be
considered a prognostic biomarker for overall survival and
risk stratification of gastric cancer, according to the 7th
TNM edition [52]. The first study [37] reports that an ADC
of 1.8 × 10-3 mm2/s may discriminate between stage I and
stage II and that values ≤ 1.36 × 10-3 mm2/s are associated
with stage III. The second paper [51] shows that an ADC ≤ 1.5
× 10-3 mm2/s is related to a negative outcome, along with T
and N stages after surgery. These results confirm the growing
interest that quantitative MR imaging in gastric cancer is
gaining in the scientific community [53].
CE-MDCT and imaging biomarkers
Five studies on CE-MDCT were relevant, and they were
assessed in full (Fig. 1).
Fig. 3 Image of a tumour of the
gastro-oesophageal junction on
T2-weighted (a and c) and
diffusion-weighted (b and d)
imaging before and after
treatment. There has been a
decrease in the conspicuity on
DW-MRI (d) and an increase in
the apparent diffusion coefficient
(ADC) value after treatment (d)
Eur Radiol
Basic concepts of texture analysis
Texture analysis provides information on the intrinsic varia-
tion of pixels within an image. In oncology, this represents a
non-invasive method to assess the heterogeneity within a tu-
mour and could reflect its intrinsic aggressive biology or treat-
ment resistance [54, 55]. There are different levels of textural
features; these range from first-order statistics (that evaluate
the grey-level distribution from pixels in a given area, such as
energy, entropy, skewness) to higher-order statistics that in-
vestigate the relationship between different voxels [56].
This is a hot topic for quantitative imaging in oncology in
order to evaluate lesion characterisation, response to therapy
and prognosis [56]. However, there is still marked variability
in methods and post-processing techniques in addition to the
need to identify the key parameters among hundreds of poten-
tial imaging biomarkers from CE-MDCT [56].
A standardised CE-MDCT protocol for adequate
texture analysis in gastric cancer
An adequate CE-MDCTscan is crucial to obtain a reliable and
reproducible texture analysis for research purposes. As a rule
of thumb, the CE-MDCT scan parameters usually applied for
gastric cancer are: 120 kVp, 250 mAS, collimation 64 × 0.625
mm, 3 mm helical thickness and 1 mm reconstruction thick-
ness [57]. The first step for an adequate set of images is to
ensure a correct distension of the gastric cavity. This can be
reached by using negative endoluminal contrast agents (500–
750 ml water or gas produced by effervescent granules).
Air filling is more accurate than water filling for tumours of
the antrum; this is very important when drawing the regions of
interest (ROIs) for texture analysis, as shown in Fig. 4.
The second step is the use of an intravenous/intramuscular
anti-peristaltic agent (e.g. scopolamine-N-butyl bromide or
glucagone) similarly to DW-MRI. This reduces the mobility
of the gastric walls during the scan acquisition so that the
ROIs can be drawn on static images and easily compared for
texture analysis (Fig. 5). In this regard, the 8th TNM Staging
Manual mentions the important role of gastric distention for
the staging of gastric cancer [58]. Figure 6 is a set of different
CE-MDCT images of gastric cancer acquired using the afore-
mentioned recommendations, allowing accurate ROI delinea-
tions for texture analysis.
Texture analysis and gastric cancer
Texture analysis has been receiving much attention in the
management of gastric cancer. However, only a few studies
have been published on this topic so far [59–63], and they are
listed in Table 3.
First, there are no specific recommendations regarding the
most accurate CE-MDCT phase for texture analysis. Some stud-
ies in Table 3 were conducted in the (late) arterial phase [61, 62],
while others in the venous phase [63] or in both [59, 60].
Fig. 4 Tumour of the antrum
(arrows) using water (a; axial
view) and air filling (b; coronal
view) on contrast-enhanced
multidetector computed
tomography. Air filling is more
accurate when drawing the
regions of interest (ROIs) for
texture analysis (blue: primary
tumour; orange: pathological
lymph node)
Eur Radiol
However, the administration of intravenous contrast is impor-
tant for texture analysis, as this allows the quantification of the
vascularity before and after treatment and helps assessing the
degree of infiltration of the surrounding fat. Texture analysis
reflects some tumour features related to tissue heterogeneity at
a cellular level; this means that differences at a microscopic level
are also detectablemacroscopically byCE-MDCTimaging [56].
A closer look at the results in Table 3 reveals that texture
analysis can differentiate histological subtypes (adenocarcino-
ma, lymphoma and gastrointestinal stromal tumours) [59].
Similar results have been published by Liu et al [60]; the
authors found that texture parameters can predict the degree
of differentiation, Lauren classification and vascular invasion.
There is also evidence that textural features can predict
Fig. 5 Comparison between a
protocol without and with
administration of anti-peristaltic
agent on multidetector computed
tomography. The image shows
how the region of interest (ROI)
delineation is more reproducible
at different time points in the
second scenario. Unenhanced (a
and d), arterial (b and e) and
portal (c and f) phases
Fig. 6 Contrast-enhancedmultidetector computed tomography images of
different gastric cancers (arrows) that have been acquired using a standard
protocol, thus allowing accurate regions of interest for texture analysis (a,
b, e, taken as an example)
Eur Radiol
treatment response [61] when the response rate is based on
TRG [49]. Like DW-MRI, quantitative imaging from texture
analysis is associated with the prognosis of untreated [62] and
treated [63] gastric cancer. The studies presented in Table 3
offer compelling evidence that CE-MDCT-based texture anal-
ysis holds promise in the management of gastric cancer, even
though further studies are necessary before widespread appli-
cation of this technique in common clinical practice.
Limitations
Results so far have been encouraging but have given rise to
many questions in need of further investigation as they limit
the application of imaging biomarkers in daily clinical prac-
tice. First, the large variability in the selection of imaging
acquisition parameters for DW-MRI and CE-MDCT (e.g.
standardised b values, arterial vs. venous phase) is a consid-
erable challenge. Future studies should aim at standardising
data-acquisition protocols as well as validating new methods
to extract quantitative parameters from imaging techniques
(e.g. ROI assessment).
Second, multicentre trials on large cohorts of patients have
yet to be carried out. Focused groups of researchers willing to
perform multicentre, international studies are needed to ad-
dress the key questions related to imaging biomarkers for gas-
tric cancer [64]. The radiological community should continue
to play an active role in the academic research by providing
valuable expertise to incorporate imaging biomarkers into fu-
ture clinical trials.
Conclusions
As emerged from this paper, imaging biomarkers are promis-
ing tools of modern radiology [65, 66] and could become an
essential cornerstone for gastric cancer therapy. Despite these
limitations, this review highlights the great potential of ADC
and texture analysis for gastric cancer. This is a vital issue for
future guidelines, especially in the era of Bpersonalised
medicine^, where the goal is to tailor specific treatments for
each single patient.
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